| __timestamp | Takeda Pharmaceutical Company Limited | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 5078000000 |
| Thursday, January 1, 2015 | 650773000000 | 4717000000 |
| Friday, January 1, 2016 | 619061000000 | 5096000000 |
| Sunday, January 1, 2017 | 628106000000 | 4986000000 |
| Monday, January 1, 2018 | 717599000000 | 4214000000 |
| Tuesday, January 1, 2019 | 964737000000 | 3806000000 |
| Wednesday, January 1, 2020 | 875663000000 | 3671000000 |
| Friday, January 1, 2021 | 886361000000 | 3528000000 |
| Saturday, January 1, 2022 | 997309000000 | 3445000000 |
| Sunday, January 1, 2023 | 1053819000000 | 3498000000 |
| Monday, January 1, 2024 | 1053819000000 | 3702000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Limited, two industry titans, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Takeda's SG&A expenses have surged by approximately 72%, reaching a peak in 2023. This growth reflects Takeda's aggressive expansion and strategic investments, positioning it as a formidable force in the global market.
Conversely, Teva's SG&A expenses have seen a gradual decline, dropping by about 31% over the same period. This trend suggests a focus on cost optimization and efficiency, crucial for maintaining competitiveness amidst industry challenges.
It's noteworthy that data for Teva in 2024 is unavailable, indicating potential reporting delays or strategic shifts.
Eli Lilly and Company and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of GSK plc and Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs TG Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited and Merus N.V.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Veracyte, Inc. Trends and Insights
Teva Pharmaceutical Industries Limited and Geron Corporation: SG&A Spending Patterns Compared